Quest for the right Drug
בטרן S.R. 100 BETAREN 100 S.R. (DICLOFENAC SODIUM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות בשחרור איטי : TABLETS SLOW RELEASE
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common: (>1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000); Not known: cannot be estimated from the available data. The following undesirable effects include those reported with either short-term or long-term use. Table 1 Blood and lymphatic system disorders Very rare Thrombocytopenia, leucopoenia, anaemia (including haemolytic and aplastic anaemia), agranulocytosis. Immune system disorders Rare Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock). Very rare Angioneurotic oedema (including face oedema). Psychiatric disorders Very rare Disorientation, depression, insomnia, nightmare, irritability, psychotic disorder. Nervous system disorders Common Headache, dizziness. Rare Somnolence, tiredness. Very rare Paraesthesia, memory impairment, convulsion, anxiety, tremor, aseptic meningitis, taste disturbances, cerebrovascular accident. Unknown Confusion, hallucinations, disturbances of sensation, malaise. Eye disorders Very rare Visual disturbance, vision blurred, diplopia. Unknown Optic neuritis. Ear and labyrinth disorders Common Vertigo. Very rare Tinnitus, hearing impaired. Cardiac disorders Uncommon* Myocardial infarction, cardiac failure, palpitations, chest pain. Unknown Kounis syndrome Vascular disorders Very rare Hypertension, hypotension, vasculitis. Respiratory, thoracic and mediastinal disorders Rare Asthma (including dyspnoea). Very rare Pneumonitis. Gastrointestinal disorders Common Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia. Rare Gastritis, gastrointestinal haemorrhage, haematemesis, diarrhoea haemorrhagic, melaena, gastrointestinal ulcer with or without bleeding or perforation (sometimes fatal particularly in the elderly). Very rare Colitis (including haemorrhagic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, oesophageal disorder, diaphragm-like intestinal strictures, pancreatitis. Unknown Ischaemic colitis Hepatobiliary disorders Common Transaminases increased. Rare Hepatitis, jaundice, liver disorder. Very rare Fulminant hepatitis, hepatic necrosis, hepatic failure. Skin and subcutaneous tissue disorders Common Rash. Rare Urticaria. Very rare Bullous eruptions, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), dermatitis exfoliative, loss of hair, photosensitivity reaction, purpura, allergic purpura, pruritus. Renal and urinary disorders Very rare Acute renal failure, haematuria, proteinuria, nephrotic syndrome, interstitial nephritis, renal papillary necrosis. Reproductive system and breast disorders Very rare Impotence General disorders and administration site conditions Rare Oedema *The frequency reflects data from long-term treatment with a high dose (150mg/day). Clinical trial and epidemiological data consistently point towards an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high dose (150 mg daily) and in long term treatment (see sections 4.3 and 4.4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Rheumatoid arthritis & osteoarthritis
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
עלון מידע לצרכן
23.09.21 - עלון לצרכן אנגלית 07.04.21 - עלון לצרכן עברית 09.08.21 - עלון לצרכן עברית 23.09.21 - עלון לצרכן עברית 23.09.21 - עלון לצרכן ערבית 14.11.23 - עלון לצרכן עברית 08.01.24 - עלון לצרכן עברית 28.03.24 - עלון לצרכן אנגלית 28.03.24 - עלון לצרכן עברית 28.03.24 - עלון לצרכן ערבית 29.11.11 - החמרה לעלון 07.04.21 - החמרה לעלון 09.08.21 - החמרה לעלון 18.11.12 - החמרה לעלון 14.11.23 - החמרה לעלון 08.01.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
בטרן S.R. 100